
The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.
Access to comprehensive care is key to successful care of children with special needs and their families, an American Academy of Pediatrics (AAP) report notes, and the AAP offers specific suggestions for how to accomplish this.
Access to comprehensive care is key to successful care of children with special needs and their families, an American Academy of Pediatrics (AAP) report notes, and the AAP offers specific suggestions for how to accomplish this.






